×ðÁú¿­Ê±

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ת»¯Ò½Ñ§¡ª¡ª¼ÓËÙÁ¢ÒìÒ©ÎïºÍ¾«×¼Ò½Ñ§Ñз¢Àú³Ì

2022-12-16
|
»á¼ûÁ¿£º

ת»¯Ò½Ñ§ÒÔÒ©ÎïÑз¢Àú³ÌÖÐÉúÎï±ê¼ÇÎïΪ½¹µã£¬ÒÔ¾«×¼Ò½ÁÆÌá¸ßÒ©ÎïÑз¢ÁÙ´²Ó¦´ðÂÊΪĿµÄ£¬ÁýÕÖ´ÓÔçÆÚ°ÐµãÈ·ÈÏ¡ª¡ªÁÙ´²Ç°R&D ¡ª¡ªÁÙ´²I¡¢II¡¢IIIÆÚDevelopment£¬µ½ÉÏÊкóµÄÒ©Îï¼ì²â£¬Í¨¹ý²î±ð½×¶ÎµÄÑо¿ÊµÏÖÒ©ÎïÑз¢µÄ±Õ»· ¡£

×ðÁú¿­Ê±×ª»¯Ò½Ñ§Æ½Ì¨ÓµÓÐÂÄÀú¸»ºñµÄרҵ»¯ÊÖÒÕÍŶÓ£¬´ÓÒ©Îï°ÐµãµÄ×÷ÓûúÖÆºÍÉúÎï±ê¼ÇÎïµÄÁÙ´²Ó¦Óóö·¢£¬ÒÔÉúÎï±ê¼ÇÎïµÄ·¢Ã÷ºÍÑé֤Ϊ»ù´¡£¬Á¬Ïµ¶àÖÖ²î±ðµÄÊÖÒÕÆ½Ì¨ºÍÏȽøµÄÒÇÆ÷£¬ ½¨ÉèÁ˶àÖÖÉúÎïÆÊÎöÒªÁ죬½µµÍÁËÒ©ÎïÑз¢µÄ±¾Ç®ºÍʱ¼ä£¬Îª²î±ðÀàÐ͵ÄÒ©Îï¡¢²î±ðÀàÐ͵ÄÒ©ÆóºÍ²î±ðÑз¢½×¶ÎµÄÏîÄ¿Ìṩ¶àÔª¸ßЧµÄЧÀÍ ¡£

Ëæ×Å»ùÒò×éѧ¡¢ÂѰ×ÖÊ×éѧºÍ´úл×éѧµÈ¶à×éѧÆÊÎöÊÖÒÕÒ»Ö±µØÉú³¤£¬ÖÎÁÆ·½·¨ÒѾ­´Ó¹Å°åС·Ö×ÓÀ©Õ¹µ½¶àëÄ¡¢ÂѰס¢¿¹Ìå¡¢»ùÒòÁÆ·¨¡¢Ï¸°ûÁÆ·¨µÈ¶àÖÖÐÂÐÍÊÖÒÕ ¡£Ö»¹ÜÓÐÕâЩÐÂÊÖÒÕ£¬µ«ÈÔÓдó×Ú¼²²¡µÄÖ²¡Ôµ¹ÊÔ­ÓÉ»¹ÎÞ·¨³¹µ×Ã÷È· ¡£×ª»¯Ò½Ñ§½«ÉúÎïҽѧÊÓ²ìºÍÑо¿×ª»¯Îª¸ÄÉÆ¿µ½¡µÄ¸ÉÔ¤²½·¥µÄÀú³Ì£¬¼ÓËÙÁË»ù´¡Ñо¿¡¢ÐÂÒ©¿ª·¢µÄºÍÁÙ´²×ª»¯µÄÀú³Ì£¬³ÉΪ¾«×¼°ÐÏòÖÎÁƵļÓËÙÆ÷ ¡£×ª»¯Ò½Ñ§Ñо¿Ê¹ÓÃÖÖÖÖÑо¿ÊֶΣ¬È·¶¨°ÐµãÓë¼²²¡±¬·¢Éú³¤µÄ¹ØÏµ¡¢ÑéÖ¤ºÍ̽Ë÷Ò©ÎïµÄ×÷ÓûúÖÆ¡¢·¢Ã÷ÉúÎï±ê¼ÇÎï²¢¿ª·¢ÅãͬÕï¶Ï²úÆ·£¬ÒÔ¼°ÎªÁÙ´²Ñо¿¿ªÕ¹É¸Ñ¡×îºÏÊʵÄÈËȺºÍ˳Ӧ֢µÈ£¬´Ó¶øÌá¸ßÐÂÒ©Ñз¢Ð§ÂʺÍÀÖ³ÉÂÊ ¡£

½«×ª»¯Ò½Ñ§Àï³Ì±®µþ¼Óµ½Ò©Î↑·¢½×¶Î.jpg

½«×ª»¯Ò½Ñ§Àï³Ì±®µþ¼Óµ½Ò©Î↑·¢½×¶Î[1]

ÉúÎï±ê¼ÇÎïÑо¿Æ½Ì¨

ÉúÎï±ê¼ÇÎBiomarker£©Í¨³£ÊÇÖ¸Äܱ»¿Í¹ÛÕÉÁ¿ºÍÆÀ¼Û£¬·´Ó¦ÐÄÀí»ò²¡ÀíÀú³Ì£¬ÒÔ¼°¶Ô̻¶»òÖÎÁƸÉÔ¤²½·¥±¬·¢ÉúÎïѧЧӦµÄÖ¸±ê ¡£ÉúÎï±ê¼ÇÎï¶àȪԴÓÚÈËÌå×éÖ¯»òÌåÒº£¬¿Éº­¸ÇÐÄÀí¡¢Éú»¯¡¢ÃâÒß¡¢Ï¸°ûºÍ·Ö×ÓµÈˮƽµÄ¸Ä±ä ¡£

ÉúÎï±ê¼ÇÎïµÄ¼ì²â¿ÉÆÕ±éµØÓ¦ÓÃÓ벡È˵Äɸ²é¡¢Õï¶Ï¡¢ÁÙ´²Ñо¿¡¢Ö¸µ¼ÓÃÒ©¡¢Ô¤ºóµÈÁìÓò ¡£¿ÉÌá¸ß»ùÓÚ»ùÒò×éѧ¡¢ÂѰ××éѧ¡¢Ï¸°û×éѧ¡¢²¡Àí×éѧµÈ¶à×éѧµÄÉúÎï±ê¼ÇÎï·¢Ã÷¼°Ñé֤ЧÀÍ ¡£ÎªÉúÎï±ê¼ÇÎïÑо¿Ìṩ¿ÆÑ§Ö§³Ö£¬¶à²ãÃæÖúÁ¦ÐÂÒ©Ñз¢ÁÙ´²ÊÔÑé ¡£ÉúÎï±ê¼ÇÎï×÷Ϊ×îÖ±½Ó¿ìËÙÓÐÓõÄÕï¶ÏÊֶΣ¬ÆäɸѡÓë»ñµÃ¿ÉÔÚ¼²²¡Õï¶Ï¡¢Éú³¤¡¢ÖÎÁÆ¡¢ÒÔ¼°ÁÆÐ§¼à²âµÈ¶à¸ö·½ÃæÊ©Õ¹Ö÷ÒªµÄ×÷Óà ¡£ÉúÎï±ê¼ÇÎïÓлùÓÚDNAµÄ¡¢ÓлùÓÚRNAµÄ¡¢ÉÐÓлùÓÚÂѰ×ÖʵÄ£¬²î±ðµÄ·Ö×ÓºÍÂѰ×ÐèÒª²î±ðµÄÊÖÒÕÆ½Ì¨ ¡£Ëæ×ŸßͨÁ¿»ùÒò×éѧ¡¢ÂѰ×ÖÊ×éѧµÈµÄһֱϣÍû£¬ÉúÎï±ê¼ÇÎï°üÀ¨µÄÖÖÀàÒ²Ô½À´Ô½¶à£¬ÀýÈçSNP¡¢ÍâÃÚÌå¡¢miRNA¡¢lncRNAµÈ¶¼±»ÁÐÈëÉúÎï±ê¼ÇÎïµÄÐÐÁÐ ¡£ÏÖÔÚÒÑÓжàÖÖÊÖÒÕÆ½Ì¨±»Ó¦ÓÃÓÚÉúÎï±ê¼ÇÎïÑо¿£¬Èç°üÀ¨»ùÒò×éѧ¡¢ÂѰ×ÖÊ×éѧ¡¢ëÄ×éѧ¡¢´úл×éѧµÈÔÚÄÚµÄ×éѧƽ̨£¬ÒÔ¼°°üÀ¨ÄÉÃ×ÊÖÒÕ¡¢ÉúÎïÐÅϢѧ¡¢¿¹ÌåоƬ¡¢¸ßÄÚÔÚɸѡÊÖÒÕ¡¢ÎÞ±ê¼ÇÏ໥×÷ÓÃÆÊÎöÊÖÒյȶàÖÖÇ°ÑØÊÖÒÕÔÚÄÚµÄÊÖ¶ÎÓëÒªÁ죬¶¼Îª¿ìËÙ»ñµÃ¼°É¸Ñ¡ÉúÎï±ê¼ÇÎï´øÀ´Á˼«´óµÄ¿ÉÄÜ ¡£

ÉúÎï±ê¼ÇÎïµÄ·ÖÀ༰ÓÃ;

? Õï¶ÏÐÔÉúÎï±ê¼ÇÎÓÃÓÚ¼ì²â»òÈ·Èϼ²²¡×´Ì¬£¬»òʶ±ð²î±ð¼²²¡ÑÇÐÍ ¡£

? Ô¤ºóÐÔÉúÎï±ê¼ÇÎ·´Ó¦¼²²¡Ô¤ºóÌØÕ÷¡¢¼²²¡¸´·¢»òÏ£ÍûΣº¦ ¡£

? Õ¹ÍûÐÔÉúÎï±ê¼ÇÎÓÃÓÚÕ¹Íû»¼Õß¶ÔijÖÖÖÎÁÆ»ò¸ÉÔ¤²½·¥¿ÉÄܱ¬·¢Ä³ÖÖÁÆÐ§Ó¦´ð ¡£

? ҩЧѧÉúÎï±ê¼ÇÎ·´Ó¦»¼ÕßÔÚ½ÓÊÜÖÎÁƺ󱬷¢Ä³ÖÖÉúÎïѧӦ´ð ¡£

? Çå¾²ÐÔÉúÎï±ê¼ÇÎÓÃҩǰ»òÓÃÒ©Àú³ÌÖмà²â´Ó¶ø×èÖ¹»ò½µµÍ»¼Õß±¬·¢²»Á¼·´Ó¦ ¡£

? ¼à²âÐÔÉúÎï±ê¼ÇÎ¼à²â¼²²¡×´Ì¬×ª±ä£¨È縴·¢µÈ£© ¡£

×ðÁú¿­Ê±ÉúÎï±ê¼ÇÎï¾ÙÀý

? PD1/PD-L1

? ErbB2/HER2

? p-FGFR1/FGFR2/FGFR3¡¢p-ERK¡¢p-CREB¡¢p-AKT

? EGFR

? VEGF

? p53

? Cyclin D1

? COX-2

? Cytokeratin 7£¨CK7£©

? K-Ras

? SOX2

? MET

? Fas

? ER-¦Á

? Ki-67µÈ

×ðÁú¿­Ê±ÉúÎï±ê¼ÇÎï¾ÙÀý.jpg

×ðÁú¿­Ê±°¸Àý

Biacore T200

WBC100 ÊÇÒ»ÖÖÐÂÐͿڷþÓÐÓõķÖ×Ó½º£¬¿ÉÑ¡ÔñÐԵؽµ½â c-Myc ÂѰ׶ø¶ÔÆäËûÂѰ×ÎÞ×÷ÓûîÐÔ£¬²¢ÓÐÓÃɱËÀc-Myc¹ý±í´ïµÄ°©Ï¸°û ¡£SPRЧ¹ûÏÔʾ WBC100 Óë c-Myc ÂѰ×Á¬Ïµ£¬ÇÒ±£´æ¼ÁÁ¿ÒÀÀµÐÔ ¡£´ËSPRʵÑéÕýÊÇͨ¹ý×ðÁú¿­Ê±Ê¹ÓÃBiacore T200ÒÇÆ÷¾ÙÐеÄ ¡£

Surface-plasmon-resonance-(SPR).jpg

Surface plasmon resonance (SPR)[2]

Biacore-8K

Biacore-8K.jpg

? 8 needles and 16 flowcells, study 8 targets at the same time £»

? High-throughput, 500 compounds/day £»

? Fast detection speed£¬finish one affinity and kinetic test in 2-15 minutes.

PD-1 ºÍ VEGFÁ¬ÏµÊµÑé

PD-1-ºÍ-VEGFÁ¬ÏµÊµÑé.jpg

A: Binding kinetics of different doses of Nivolumab with PD-1 (Biacore 8K)

B: Binding kinetics of different doses of Aflibercept with recombinant human VEGF (Biacore 8K)

ÉúÎïÆÊÎöÊÖÒÕÆ½Ì¨

×ðÁú¿­Ê±ÉúÎïÆÊÎö²¿¿ÉÒÔΪ¿Í»§ÌṩС·Ö×ÓÒ©Îï¡¢´ó·Ö×ÓÉúÎïÖÆÆ·¡¢ÉúÎï±ê¼ÇÎïµÄɸѡÓ뿪·¢£¬ÒÔ¼°ÁÙ´²Ç°ºÍÁÙ´²½×¶ÎµÄÑо¿Ð§ÀÍ ¡£¿ÉÒÔÌṩÇкÏFDA/NMPA GLPµÄÉúÎïÊÖÒÕÒ©ÎïÉúÎïÆÊÎöЧÀÍ£¬ÒÔÖ§³ÖÂѰ×Ò©Îï¡¢¿¹ÌåÒ©Îï¡¢ÒßÃç¡¢ÉúÎï±ê¼ÇÎϸ°ûºÍ»ùÒòÖÎÁÆÒ©ÎïµÄÔçÆÚ¿ª·¢£¬¼°ÆäÁÙ´²Ç°Ñо¿ºÍÁÙ´²Ñо¿ ¡£

ЧÀÍÄÜÁ¦

? ÃâÒ߯ÊÎöÒªÁìµÄ¿ª·¢¼°ÒªÁìѧÑéÖ¤

? ÂѰס¢¿¹Ìå¡¢ADC¡¢¶àëÄÒ©Îï¡¢ºËËá¡¢ÒßÃ缰ϸ°ûÓë»ùÒòÖÎÁƲúÆ·µÈµÄÆÊÎö

? ÉúÎï±ê¼ÇÎïµÄɸѡ¡¢ÑéÖ¤ÓëÆÊÎö¡¢Ï¸°ûÒò×Ó¼ì²â

? ¿¹Ò©ÐÔ¿¹Ì壨ADA£©ÃâÒßÔ­ÐÔÆÊÎö

? ÒßÃçµÄÃâÒßÔ­ÐÔÆÊÎö

? ²¡¶¾µÄ»îÐÔÆÊÎö

? ÒßÃçµÄЧ¼Û²â¶¨

? ÁÙ´²ÑùÆ·ÉúÎïÆÊÎö

? Ö§³ÖPK Ò©´ú¶¯Á¦Ñ§¡¢TK ¶¾´ú¶¯Á¦Ñ§¡¢×éÖ¯ÂþÑÜÊÔÑé¡¢INDÉ걨

ЧÀÍÁÁµã

? ʵÑéÊÒʵÑéÖÜÈ«µÄÐÅÏ¢»¯ÖÎÀí£¬ÔËÓÃÑéÖ¤¹ýµÄʵÑéÊÒÐÅÏ¢ÖÎÀíϵͳ£¨Watson LIMS 7.2£©½¨ÉèÁËÍêÉÆµÄÑùÆ·ÖÎÀíÁ´ºÍʵÑéÊý¾ÝµÄ´¦Öóͷ£¡¢¸ú×ÙÓë´æ´¢Á´ £»

? SensaTronicsÎÂ¶È¼à¿ØÏµÍ³ £»

? ÑéÖ¤¹ýµÄWinNonlin Èí¼þÓÃÓÚÊý¾ÝÆÊÎö £»

? Êý¾Ý±»FDAºÍNMPA½ÓÊÜ£¬ÌṩÖÜÈ«ÇкÏFDA/NMPA/OECD GLP¹æ·¶ÒªÇóµÄÉúÎïÊÖÒÕÒ©ÎïÆÊÎöЧÀÍ £»

? ×ÔÁ¦µÄС·Ö×ÓÉúÎïÆÊÎöƽ̨ºÍÉúÎïÊÖÒÕÒ©ÆÊÎöƽ̨ £»

?ÓµÓÐSpectraMaxM4/M5/i3x, MSD, Luminex, Biacore 8K, Envision,Gyrolab£¬ABI7500 qPCR¡¢ddPCR¡¢FACSµÈÈ«·½Î»¶à¹¦Ð§µÄÊÖÒÕÆ½Ì¨ £»

? ÎÞаÔËÓÃELISA£¬ECL£¬IP£¬Co-IP£¬qPCR£¬ddPCR¡¢FACS£¬Elispot¡¢Ã¸Ñ§¡¢Cell-based µÈ¶àÖÖÒªÁ죬֧³ÖÇ°ÑØÉúÎïÒ©£¬ÖÖÀà°üÀ¨ÂѰס¢¿¹Ìå¡¢ADC¡¢¶àëÄ¡¢ºËËá¡¢ÒßÃ缰ϸ°û»ùÒòÖÎÁÆÒ©ÎïµÄÔçÆÚ¿ª·¢£¬¼°ÆäÁÙ´²Ç°Ñо¿ºÍÁÙ´²Ñо¿ £»

? ¿ª·¢²¢ÑéÖ¤Õë¶Ô½ü°Ù¸ö²î±ð°Ðµã£¬ÈçCD-4£¬CTLA-4£¬PD-1£¬PD-L1¼°T-DM1ÀàËÆÎïADCµÈµÄÆÊÎöÒªÁ죬֧³ÖPK/TK/ÃâÒßÔ­ÐÔ(Total ADA, Nab)/ÉúÎï±ê¼ÇÎï/ϸ°ûÒò×ÓÖÐÆÊÎö ¡£

ÉúÎïÆÊÎöƽ̨²¿·ÖÒÇÆ÷

ÉúÎïÆÊÎöƽ̨²¿·ÖÒÇÆ÷.jpg

×ðÁú¿­Ê±°¸Àý£ºÁÙ´²Ð¡ëÄÀà·Ö×ÓBEÑо¿

×ðÁú¿­Ê±°¸Àý£ºÁÙ´²Ð¡ëÄÀà·Ö×ÓBEÑо¿.jpg

Á÷ʽϸ°ûÊÖÒÕÆ½Ì¨

ÍùÆÚÎÄÕÂÖУ¬ÎÒÃÇͨ¹ý´ÓFACS ¼ì²â Cytokine ¼ì²âºÍϸ°û¹¦Ð§¼ì²â¶à¸öÏÖʵ°¸ÀýµÄ½Ç¶È³ö·¢£¬ÏêϸÏÈÈÝÁË¡°×ðÁú¿­Ê±Á÷ʽϸ°ûÊÖÒÕÆ½Ì¨¡±£¨µã»÷Ïàʶ£© ¡£×èÖ¹ÏÖÔÚ£¬×ðÁú¿­Ê±³Ð½ÓµÄÁ÷ʽ¼ì²âÏîÄ¿ÒѾ­½ü400Ï°üÀ¨Ï¸°ûÍâò¿¹Ô­±í´ïµÄÁ÷ʽ¼ì²â £»Ï¸°ûÔöÖ³¡¢Ï¸°û·Ö½â¡¢Ï¸°ûµòÍöµÈµÄÁ÷ʽÆÊÎö £»¶¯ÎïÍâÖÜѪ¼°¸÷ÃâÒ߯÷¹Ù¼ì²â £»ÒÆÖ²ÁöÄ£×ÓÁ÷ʽ¼ì²âµÈ ¡£×ðÁú¿­Ê±Á÷ʽ¼ì²âÍŶӽ«Ã¿Ò»¸ö°¸ÀýµÄÌØµãÓë¶àÄêʵսÂÄÀúºÍÊÖÒÕ»ýÀÛÏàÁ¬Ïµ£¬ÉóÉ÷µØ½«ÓÅÖÊʵÑéЧ¹ûÌá½»µ½¿Í»§ÊÖÉÏ£¬Ò»Á¬ÖúÁ¦¿Í»§µÄÑз¢ÏîÄ¿»ñÅú ¡£

ÃâÒß×黯ÊÖÒÕÆ½Ì¨

ÃâÒß×黯£¬Ò²³ÆÃâÒß×éÖ¯»¯Ñ§ÊÖÒÕ(immunohistochemistry)»òÃâÒßϸ°û»¯Ñ§ÊÖÒÕ(immunocytochemistry) ¡£ÊÇÖ¸Ó¦ÓÃÃâÒßѧ»ùÀ´Ô´Àí¼´¿¹Ô­Ó뿹ÌåÌØÒìÐÔÁ¬ÏµµÄÔ­Àí£¬Í¨¹ý»¯Ñ§·´Ó¦Ê¹±ê¼Ç¿¹ÌåµÄÏÔÉ«¼ÁÏÔÉ«À´È·¶¨×é֯ϸ°ûÄÚ¿¹Ô­£¨¶àëĺÍÂѰ×ÖÊ£©£¬¶ÔÆä¾ÙÐж¨Î»¡¢¶¨ÐÔ¼°Ïà¶Ô¶¨Á¿µÄÑо¿ ¡£Æ¾Ö¤¿¹Ô­¿¹Ìå·´Ó¦ºÍ»¯Ñ§ÏÔÉ«µÄÔ­Àí£¬×éÖ¯ÇÐÆ¬»òϸ°ûÑù±¾ÖеĿ¹Ô­ÏȺÍÒ»¿¹Á¬Ïµ£¬ÔÙʹÓÃÒ»¿¹Óë¶þ¿¹·´Ó¦£¬DAB¾ÙÐÐÏÔÉ«£¬½ø¶ø¾ÙÐÐÆÊÎö ¡£

Ö÷Òª°ì·¨

? ×éÖ¯´¦Öóͷ£¡¢Àο¿¡¢ÇÐÆ¬

? ¿¹Ô­ÐÞ¸´

? ³ýÈ¥ÄÚÔ´ÐÔ¹ýÑõ»¯Îïø

? ¹Ø±Õ

? Ò»¿¹¡¢¶þ¿¹·õÓý

? ¼ì²â

? ¸´È¾

ÃâÒß×黯ÊÖÒÕÆ½Ì¨Ö÷Òª°ì·¨.jpg

×éÖ¯´¦Öóͷ£¡¢Àο¿¡¢ÇÐÆ¬

×éÖ¯Àο¿¿ÉÉúÑÄ¿¹Ô­£¬±ÜÃâÊÕÂÞµÄ×éÖ¯×ÔÈܺͻµËÀ ¡£×éÖ¯°üÂñ¿ÉÔÚÇÐÆ¬Àú³ÌÖжÔ×éÖ¯Ìṩ֧³Ö£¬Ê¹ÇÐÆ¬¸ü¼áʵ ¡£

 Ê¯À¯ÇÐÆ¬±ù¶³ÇÐÆ¬
Àο¿°üÂñǰ£º¼×È©ÇÐÆ¬Ç°»òÇÐÆ¬ºó£º¼×È©¡¢¼×´¼¡¢ÒÒ´¼»ò±ûͪ
ÇÐÆ¬ÇÐÆ¬»ú±ù¶³ÇÐÆ¬»ú
Öü´æÊÒÎÂÏÂÖü´æ¶àÄê-80 ¡ãCÏÂÖü´æ1Äê £¨-190¡ãCÏÂÖü´æÊ±¼ä¸ü³¤£©
ÓÅÊÆÈÝÒײÙ×÷£¬²»»áËð»µÇÐÆ¬

? ±£´æÃ¸µÄ¹¦Ð§ºÍ¿¹Ô­ÐÔ

? ʵÑéÁ÷³Ì¼ò¶Ì£¨Í¨³£²»ÐèÒªÈß³¤µÄÀο¿°ì·¨£©

¾ÖÏÞÐÔ

? Ì«¹ýÀο¿»áÑÚÊο¹Ô­±í룬½ø¶øÔöÌí¿¹Ô­ÐÞ¸´µÄÐèÇó

? ´¦Öóͷ£Ê±¼ä³¤£ºÔÚÌݶȾƾ«ºÍ¶þ¼×±½ÖÐÖð²½ÍÑË®£¬ÒÔ±ãÓÚʯÀ¯ÉøÍ¸ ¡£

? ÈôÊÇûÓпìËÙÀä¶³×éÖ¯¡±¿ÉÄÜ»áÐγɱù¾§£¬´Ó¶øÆÆËð×éÖ¯½á¹¹

? ±ù¶³ÇÐÆ¬Í¨³£±ÈʯÀ¯ÇÐÆ¬ºñ£¬¿ÉÄܻᵼÖÂÇø·ÖÂʵ͡¢Í¼Ïñ²î

? ¿ÉÄÜÐèÒª×è¶ÏÄÚÔ´»îÐÔø ¡£

ʯÀ¯ÇÐÆ¬ vs±ù¶³ÇÐÆ¬

¿¹Ô­ÐÞ¸´

¶Ô¼×È©Àο¿µÄ×éÖ¯ÇÐÆ¬¾ÙÐп¹Ô­ÐÞ¸´£¬ÒÔ̻¶¿¹Ô­Î»µã£¬´Ó¶øÊ¹¿¹ÌåÁ¬Ïµ ¡£

 ÈÈÓÕµ¼µÄ¿¹Ô­±íλÐÞ¸´ÂѰ×Ë®½âøÓÕµ¼µÄ¿¹Ô­±íλÐÞ¸´
ÓÅÊÆ¿¹Ô­±íλµÄÐÞ¸´¸üÎÂ˳£¬²ÎÊý¸ü¿É¿Ø ¡£ÊÊÓÃÓÚ½ÏÄÑÐÞ¸´µÄ¿¹Ô­±íλ ¡£
phֵͨ³£Ê¹ÓÃpH6µÄ»º³åÒº£¬µ«¼îÐÔ»º³åÒºÒ²ÔÚÆÕ±éʹÓà ¡£±ØÐèͨ¹ýʵÑéÈ·¶¨pHֵͨ³£Îª7.4 ¡£
ζÈÔ¼95¡ãC ¡£Í¨³£Îª37¡ãC
·õÓýʱ¼ä10-20·ÖÖÓ10-15·ÖÖÓ
»º³åÒº×é·ÖÈ¡¾öÓڰп¹Ô­ËùÐèµÄpH Öµ ¡£³£ÓõĻº³åÒº°üÀ¨ÄûÃÊËáÄÆ¡¢EDTAºÍTris-EDTAø(ÈçθÂѰ×ø¡¢ÂѰ×øK »òÒÈÂѰ×ø)µÄÖÐÐÔ»º³åÒº ¡£
×¢ÖØÊÂÏî΢²¨Â¯¼ÓÈÈ¿ÉÄܻᵼÖ¿¹Ô­ÐÞ¸´²»ÔȳÆ ¡£Ç¿ÁÒ»¶Ï²»áµ¼ÖÂÍÑÆ¬(×éÖ¯ÓëÔØ²£Æ¬ÊèÉ¢£© ¡£Ã¸ÐÞ¸´ÓÐʱ»áÆÆËðÇÐÆ¬µÄÐÎ̬- Ũ¶ÈºÍʱ¼äÐèÒªÓÅ»¯

¿¹Ô­ÐÞ¸´µÄÖ÷ÒªÒªÁì

¹Ø±Õ

ÓÃѪÇå»òBSA¹Ø±Õ£¬±ÜÃ⿹ÌåµÄ·ÇÌØÒìÐÔÁ¬Ïµ£¬²¢½µµÍÅä¾°ºÍDZÔڵļÙÑôÐÔЧ¹û ¡£

? ÂѰ׹رգºÊ¹ÓÃѪÇå»òBSA ¾ÙÐйرչØÓÚ±ÜÃ⿹ÌåÓë×éÖ¯»òFc ÊÜÌ壨Ó뿹Ìåºã¶¨Çø£¨Fc£©Á¬ÏµµÄÊÜÌ壩±¬·¢·ÇÌØÒìÐÔÁ¬ÏµÖÁ¹ØÖ÷Òª ¡£¶þ¿¹ÖÖÊôȪԴµÄѪÇåÊǺܺõĹرÕÊÔ¼Á ¡£Ê¹ÓÃţѪÇå°×ÂѰף¨BSA£©»òÀÒÂѰ×£¬¿ÉÓÃÓÚ×è¶Ï·ÇÌØÒìÐÔ¿¹ÌåÁ¬Ïµ ¡£

? ÉúÎïËØ¹Ø±Õ£ºÔÚʹÓûùÓÚÇ׺ÍËØ/ÉúÎïËØµÄ¼ì²âϵͳʱ£¬×è¶ÏÄÚÔ´ÐÔÉúÎïËØ£¬ÓÉÓÚÄÚÔ´ÐÔÉúÎïËØ±£´æÓÚÐí¶à×éÖ¯ÖУ¬ÌØÊâÊÇÉöÔࡢƢÔà¡¢¸ÎÔàºÍ´óÄÔÖÐ ¡£ÓÃÇ׺ÍËØÓë×éÖ¯·õÓý£¬×è¶ÏÄÚÔ´ÉúÎïËØ£¬È»ºóÓÃÍâÔ´ÉúÎïËØ·õÓý£¬ÒÔ×è¶ÏÇ׺ÍËØ·Ö×ÓÉÏÌØÁíÍâÉúÎïËØÁ¬ÏµÎ»µã ¡£

¼ì²â

ÓÃѪÇå»òBSA¹Ø±Õ£¬±ÜÃ⿹ÌåµÄ·ÇÌØÒìÐÔÁ¬Ïµ£¬²¢½µµÍÅä¾°ºÍDZÔڵļÙÑôÐÔЧ¹û ¡£

? øÏÔÉ«·¨£ºÏÔÉ«¼ì²âʹÓÃøÄܹ»´ß»¯¿ÉÈÜÐÔµ×Îﱬ·¢ÓÐÉ«³Áµí ¡£ÕâЩøͨ³£Å¼ÁªÔÚ¶þ¿¹ÉÏ£¬Ò²¿ÉÒÔżÁªÔÚÒ»¿¹ÉÏÓÃÓÚÖ±½Ó¼ì²â ¡£×î³£ÓõÄøÓÐHRP ºÍAP£¬Ç°Õß½«DAB ת»¯³Éרɫ²úÆ·£¬ºóÕß½«3-°±»ù-9-ÒÒ»ùßÇßò (AEC) ת»¯³ÉºìÉ«²úÆ· ¡£ÏÔÉ«¼ì²âͨ³£±ÈÓ«¹â¼ì²â¸üѸËÙ ¡£±ðµÄ£¬²î±ðÓÚÓ«¹âȾÁÏ£¬ÓÐÉ«³ÁµíÎïÓйâÎȹÌÐÔ£¬Òò´ËȾɫÇÐÆ¬Äܹ»ÉúÑĶàÄê ¡£Ó«¹â¼ì²âÐèҪʹÓÃרҵӫÏÊÃ÷΢¾µºÍÂË¹âÆ¬£¬ÏÔÉ«¼ì²â½öÐèʹÓñê×¼ÏÔ΢¾µ ¡£È»¶ø£¬ÏÔÉ«¼ì²âµÄ·õÓýºÍ¹Ø±Õ°ì·¨±ÈÓ«¹â·¨¸ü¶à£¬Ê±¼äÒ²¸ü³¤ ¡£

? Ó«¹â·¨£ºÓ«¹â¼ì²â£¨ÃâÒßÓ«¹â£©ÊÇ»ùÓÚÓ«¹â»ùÍű»Ìض¨²¨³¤µÄ¹âÒý·¢ºó·¢É䲨³¤½Ï³¤µÄÓ«¹âµÄÌØÕ÷ ¡£Ó«¹â¼ì²â¾­³£ÓÃÓÚÐèҪͬʱ¼ì²â¶àÖÖ¿¹Ô­µÄÇéÐÎ ¡£Ó«¹âȾÁÏ¿ÉÒÔÓëÒ»¿¹»ò¶þ¿¹Ö±½ÓżÁª£¬Ò²¿ÉÓëÁ´Ã¹ËØÇ׺ÍËØÅ¼Áª ¡£

ÒÇÆ÷×°±¸£¨²¿·Ö¾ÙÀý£©

°¸ÀýÉÍÎö

ÃâÒß×黯ÊÖÒÕÆ½-°¸ÀýÉÍÎö.jpg

IHC Analysis of the expression of a)PD-L1 from lung adenocarcinoma[3]; b)Ki-67 from periampullary tumors[4]; c)Her2 from lung tumor[5]; d)CD31 from human gastric adenocarcinoma[6]; e)CD163 (M2 TAM marker) from oral squamous cell carcinoma (OSCC)[7]; f)FoxP3 from human glioblastoma[8].

×ܽáÓëÕ¹Íû

»ùÓÚ»ùÒò×éѧ¡¢ÂѰ××éѧ¡¢Ï¸°û×éѧ¼°²¡Àí×éѧµÈ×ÛºÏÐÔת»¯Ò½Ñ§Æ½Ì¨ £»¸ßÖÊÁ¿µÄÑз¢ÖÎÀíÍÅ¶Ó £»×ðÁú¿­Ê±×ª»¯Ò½Ñ§Æ½Ì¨ÖÂÁ¦ÓÚΪȫÇòÏàÖúͬ°éÌṩȫ·½Î»ÉúÎï±ê¼ÇÎï·¢Ã÷¡¢°ÐµãÑéÖ¤¡¢ÅãͬÕï¶Ï¿ª·¢ÓëÉÌÒµ»¯¼ì²âµÈÒ»Ì廯½â¾ö¼Æ»® ¡£

? ÒÔELISA¡¢ECL£¨MSD), SIMOA£¨HD-X), Biacore 8K ÊÖÒÕ¹¹½¨µÄµÄÂѰ×ÖÊÏ໥×÷Óã¬ÂѰ×ˮһÉúÎï±ê¼ÇÎïÆ½Ì¨ £»

? ÒÔÁ÷ʽϸ°ûÊõ£¨BD Symphony A3£¬BD Fortesssa, Beckman CytoFLEX S£©ÎªÖ÷¹¹½¨µÄϸ°ûˮһÉúÎï±ê¼ÇÎïÆ½Ì¨ £»

? ÒÔÓ«¹â¶¨Á¿PCRÊÖÒÕ¹¹½¨µÄ¶àÖØºËËáˮһÉúÎï±ê¼ÇÎïÆ½Ì¨ £»

? ÃâÒß×黯£¨TAMs-IHC£¬FISH£©ÊÖÒÕ¹¹½¨µÄ²¡ÀíˮһÉúÎï±ê¼ÇÎïÆ½Ì¨µÈ £»

ÖÂÁ¦ÓÚ½â¾öÁ¢ÒìÒ©ÎïµÄÑоÙʵ㣬ÖúÁ¦¾«×¼Ò½ÁÆ£¡

ÎÒÃǺÜÐÒÔ˵ØÉúÑÄÔÚÒ»¸öÉúÎïҽѧ¿ÆÑ§¿´ËÆÎÞÏÞ¿ÉÄܵÄʱ´ú ¡£ÔÚÕâ¸öʱ´ú£¬Ñо¿µÄÎÊÌâ²»ÔÙÖ÷ÒªÊÜÊÖÒÕÄÜÁ¦µÄÏÞÖÆ ¡£×ª»¯Ò½Ñ§µÄʵÏÖÐèҪͬÑùÒ»Á¬´óµ¨µÄÔ¸¾°ºÍÖ´ÐÐ ¡£ÔÚÒÑÍù¼¸Ê®Ä꣬ת»¯Ò½Ñ§È¡µÃÁËÏÔÖøÇ°½ø£¬Î´À´×ª»¯Ò½Ñ§½«¼ÌÐøÉú³¤£¬²¢¸ü¿ì¡¢¸ü¸ßЧµØÎª¸ü¶à»¼ÕßÌṩ¸ü¶àÖÎÁƵĿÉÄÜÐÔ£¡

²Î¿¼ÎÄÏ×

[1] Hugues Dolgos, et al. Translational Medicine Guide transforms drug development processes: the recent Merck experience. Drug Discov Today. 2016 Mar;21(3):517-26. doi: 10.1016/j.drudis.2016.01.003.

[2] Ying Xu, et al. A Selective Small-Molecule c-Myc Degrader Potently Regresses Lethal c-Myc Overexpressing Tumors. Adv Sci (Weinh). 2022 Mar;9(8):e2104344. doi: 10.1002/advs.202104344.

[3] Jonas J Heymann, et al. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol. 2017 Dec;125(12):896-907. doi: 10.1002/cncy.21937.

[4] Mark M Aloysius, et al. Predictive value of tumor proliferative indices in periampullary cancers: Ki-67, mitotic activity index (MI) and volume corrected mitotic index (M/V) using tissue microarrays. World J Surg. 2010 Sep;34(9):2115-21. doi: 10.1007/s00268-010-0681-3.

[5] Montse Verdu, et al. Cross-reactivity of EGFR mutation-specific immunohistochemistry assay in HER2-positive tumors. Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):565-70.

[6] Qingling Wang, et al.  EPCR promotes MGC803 human gastric cancer cell tumor angiogenesis in vitro through activating ERK1/2 and AKT in a PAR1-dependent manner. Oncol Lett. 2018 Aug;16(2):1565-1570. doi: 10.3892/ol.2018.8869.

[7] Faustino J Su¨¢rez-S¨¢nchez, et al. Macrophages in Oral Carcinomas: Relationship with Cancer Stem Cell Markers and PD-L1 Expression. Cancers (Basel) (IF: 6.13; Q1). 2020 Jul 2;12(7):1764. doi: 10.3390/cancers12071764.

[8] Qi Yue, et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol. 2014 Jan;116(2):251-9. doi: 10.1007/s11060-013-1314-0. Epub 2013 Nov 26.[9] Christopher P Austin.Opportunities and challenges in translational science. Clin Transl Sci. 2021 Sep;14(5):1629-1647. doi: 10.1111/cts.13055.

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿